Jeffrey A. Cohen | |
|---|---|
| Born | October 14, 1954 |
| Scientific career | |
| Institutions | Cleveland Clinic (Staff Neurologist) |
Jeffrey Alan Cohen (born October 14, 1954) is an American neurologist specializing in multiple sclerosis and Director of Experimental Neurotherapeutics at the Cleveland Clinic Mellen Center for Multiple Sclerosis.
Education
B.A. - Connecticut College, New London, Connecticut M.D. - University of Chicago Pritzker School of Medicine Chicago, Illinois Postdoctoral training - Neurology - University of Pennsylvania
Notable contributions
- Global Principal Investigator of the ACT (Avonex Combination Trial) clinical trial[1]
- Global Principal Investigator of the TRANSFORMS Phase III trial of Fingolimod, a novel oral agent for use in treating Multiple Sclerosis, the primary results of which were presented at the American Academy of Neurology Annual Meeting in May 2009.[2]
- Global Principal Investigator of the IMPACT trial, the first study to use the MS Functional Composite as the primary outcome measure in a clinical trial.[3]
- Co-Editor of the textbook "Multiple Sclerosis Therapeutics", ISBN 1841845256[4]
- Fellowship Director of the Mellen Center for MS National Multiple Sclerosis Society-supported Fellowship
References
- ↑ "ACT primary results manuscript".
- ↑ "Oral Fingolimod Superior to Interferon Beta1-a in RRMS". Medscape.
- ↑ "IMPACT primary results manuscript".
- ↑ Minkoff, Eli; Baker, Eli (March 6, 2007). Multiple Sclerosis Therapeutics. CRC Press. ISBN 9780203012055 – via Google Books.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.